Clinical Trial Update: A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating nivolumab with or without docetaxel in patients previously treated with advanced or metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• nivolumab (nivolumab)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Carcinoma, Non-Small-Cell Lung, Docetaxel | Phase 2 | Status: UNKNOWN